Practice patterns in osteoporosis prevention in patients on glucocorticoids [1]

M. Naunton, M. Duyvendak, G. M. Peterson, J. R B J Brouwers

Research output: Contribution to journalLetter

2 Citations (Scopus)

Abstract

We have read the recent results from the study on osteoporosis prevention in chronic (>90 days) glucocorticoid users by Feldstein et al. [1] and have three comments. 1. We believe that any apparent under-treatment may be partly due to the fact that the data analysed were collected from January 2000–December 2001. The American College of Rheumatology (ACR) guidelines for prevention of glucocorticoid-induced osteoporosis were published in July 2001 and recommended that osteoporosis prevention should be considered in those patients treated on ≥5 mg of prednisolone per day [3]. The guidelines available before this suggested that patients should be considered for osteoporosis prevention if the dose was greater than 7.5 mg per day, and the patients were treated for >6 months with the glucocorticoid [4]. We believe to be fair to the prescribers and other primary-care clinicians it should be noted that at the time that these data were collected most would only be aware that patients treated with ≥7.5 mg prednisolone should be considered for osteoporosis prevention.
Original languageEnglish
Pages (from-to)634-635
Number of pages2
JournalOsteoporosis International
Volume17
Issue number4
DOIs
Publication statusPublished - 1 Apr 2006
Externally publishedYes

Fingerprint

Glucocorticoids
Osteoporosis
Prednisolone
Guidelines
Primary Health Care
Therapeutics

Cite this

Naunton, M. ; Duyvendak, M. ; Peterson, G. M. ; Brouwers, J. R B J. / Practice patterns in osteoporosis prevention in patients on glucocorticoids [1]. In: Osteoporosis International. 2006 ; Vol. 17, No. 4. pp. 634-635.
@article{341c76957b354517890f8ef5a47d0ce5,
title = "Practice patterns in osteoporosis prevention in patients on glucocorticoids [1]",
abstract = "We have read the recent results from the study on osteoporosis prevention in chronic (>90 days) glucocorticoid users by Feldstein et al. [1] and have three comments. 1. We believe that any apparent under-treatment may be partly due to the fact that the data analysed were collected from January 2000–December 2001. The American College of Rheumatology (ACR) guidelines for prevention of glucocorticoid-induced osteoporosis were published in July 2001 and recommended that osteoporosis prevention should be considered in those patients treated on ≥5 mg of prednisolone per day [3]. The guidelines available before this suggested that patients should be considered for osteoporosis prevention if the dose was greater than 7.5 mg per day, and the patients were treated for >6 months with the glucocorticoid [4]. We believe to be fair to the prescribers and other primary-care clinicians it should be noted that at the time that these data were collected most would only be aware that patients treated with ≥7.5 mg prednisolone should be considered for osteoporosis prevention.",
author = "M. Naunton and M. Duyvendak and Peterson, {G. M.} and Brouwers, {J. R B J}",
year = "2006",
month = "4",
day = "1",
doi = "10.1007/s00198-005-0055-0",
language = "English",
volume = "17",
pages = "634--635",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer",
number = "4",

}

Practice patterns in osteoporosis prevention in patients on glucocorticoids [1]. / Naunton, M.; Duyvendak, M.; Peterson, G. M.; Brouwers, J. R B J.

In: Osteoporosis International, Vol. 17, No. 4, 01.04.2006, p. 634-635.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Practice patterns in osteoporosis prevention in patients on glucocorticoids [1]

AU - Naunton, M.

AU - Duyvendak, M.

AU - Peterson, G. M.

AU - Brouwers, J. R B J

PY - 2006/4/1

Y1 - 2006/4/1

N2 - We have read the recent results from the study on osteoporosis prevention in chronic (>90 days) glucocorticoid users by Feldstein et al. [1] and have three comments. 1. We believe that any apparent under-treatment may be partly due to the fact that the data analysed were collected from January 2000–December 2001. The American College of Rheumatology (ACR) guidelines for prevention of glucocorticoid-induced osteoporosis were published in July 2001 and recommended that osteoporosis prevention should be considered in those patients treated on ≥5 mg of prednisolone per day [3]. The guidelines available before this suggested that patients should be considered for osteoporosis prevention if the dose was greater than 7.5 mg per day, and the patients were treated for >6 months with the glucocorticoid [4]. We believe to be fair to the prescribers and other primary-care clinicians it should be noted that at the time that these data were collected most would only be aware that patients treated with ≥7.5 mg prednisolone should be considered for osteoporosis prevention.

AB - We have read the recent results from the study on osteoporosis prevention in chronic (>90 days) glucocorticoid users by Feldstein et al. [1] and have three comments. 1. We believe that any apparent under-treatment may be partly due to the fact that the data analysed were collected from January 2000–December 2001. The American College of Rheumatology (ACR) guidelines for prevention of glucocorticoid-induced osteoporosis were published in July 2001 and recommended that osteoporosis prevention should be considered in those patients treated on ≥5 mg of prednisolone per day [3]. The guidelines available before this suggested that patients should be considered for osteoporosis prevention if the dose was greater than 7.5 mg per day, and the patients were treated for >6 months with the glucocorticoid [4]. We believe to be fair to the prescribers and other primary-care clinicians it should be noted that at the time that these data were collected most would only be aware that patients treated with ≥7.5 mg prednisolone should be considered for osteoporosis prevention.

UR - http://www.scopus.com/inward/record.url?scp=33645211707&partnerID=8YFLogxK

U2 - 10.1007/s00198-005-0055-0

DO - 10.1007/s00198-005-0055-0

M3 - Letter

VL - 17

SP - 634

EP - 635

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 4

ER -